A carregar...
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes
The novel sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin has recently been reported to improve glycemic control in streptozotocin-induced type 1 diabetic rats in an insulin-independent manner, via an increase in urinary glucose output. We investigated the potential of empagliflozin...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4726656/ https://ncbi.nlm.nih.gov/pubmed/26807719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0147391 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|